186 related articles for article (PubMed ID: 19908041)
21. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
[TBL] [Abstract][Full Text] [Related]
22. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy.
Ricciardelli I; Brewin J; Lugthart G; Albon SJ; Pule M; Amrolia PJ
Am J Transplant; 2013 Dec; 13(12):3244-52. PubMed ID: 24266973
[TBL] [Abstract][Full Text] [Related]
23. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
24. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
25. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas.
Cohen JI; Bollard CM; Khanna R; Pittaluga S
Leuk Lymphoma; 2008; 49 Suppl 1(Suppl 1):27-34. PubMed ID: 18821430
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
27. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).
Savoldo B; Goss JA; Hammer MM; Zhang L; Lopez T; Gee AP; Lin YF; Quiros-Tejeira RE; Reinke P; Schubert S; Gottschalk S; Finegold MJ; Brenner MK; Rooney CM; Heslop HE
Blood; 2006 Nov; 108(9):2942-9. PubMed ID: 16835376
[TBL] [Abstract][Full Text] [Related]
28. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.
O'Reilly RJ; Prockop S; Oved JH
Front Immunol; 2023; 14():1290059. PubMed ID: 38274824
[TBL] [Abstract][Full Text] [Related]
29. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.
Comoli P; Labirio M; Basso S; Baldanti F; Grossi P; Furione M; Viganò M; Fiocchi R; Rossi G; Ginevri F; Gridelli B; Moretta A; Montagna D; Locatelli F; Gerna G; Maccario R
Blood; 2002 Apr; 99(7):2592-8. PubMed ID: 11895798
[TBL] [Abstract][Full Text] [Related]
30. Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.
Zhou L; Lu DP
Virol J; 2019 Feb; 16(1):19. PubMed ID: 30736814
[TBL] [Abstract][Full Text] [Related]
31. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
[TBL] [Abstract][Full Text] [Related]
33. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant.
Heslop HE; Perez M; Benaim E; Rochester R; Brenner MK; Rooney CM
J Clin Apher; 1999; 14(3):154-6. PubMed ID: 10540372
[TBL] [Abstract][Full Text] [Related]
34. LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders.
Hong J; Ni J; Ruan M; Yang M; Dong Q; Li Q
Int J Hematol; 2020 Jun; 111(6):851-857. PubMed ID: 32162095
[TBL] [Abstract][Full Text] [Related]
35. Non-uniform
Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
Front Immunol; 2019; 10():2489. PubMed ID: 31736946
[TBL] [Abstract][Full Text] [Related]
36. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
[TBL] [Abstract][Full Text] [Related]
37. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes.
Emanuel DJ; Lucas KG; Mallory GB; Edwards-Brown MK; Pollok KE; Conrad PD; Robertson KA; Smith FO
Transplantation; 1997 Jun; 63(11):1691-4. PubMed ID: 9197369
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
[TBL] [Abstract][Full Text] [Related]
39. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
